Context Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 21, 2024
CNTX$0.19-6.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · TotalStockholders’Equity | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||
| Balance at January 1, 2022 | 15,966,053 | $15,966 | $77,510,809 | $(29,254,440) | $48,272,335 | ||||
| Fair value of warrants issued for services | — | — | 345,530 | — | 345,530 | ||||
| Share-based compensation expense | — | — | 976,440 | — | 976,440 | ||||
| Net loss | — | — | — | (14,835,939) | (14,835,939) | ||||
| Balance at December 31, 2022 | 15,966,053 | $15,966 | $78,832,779 | $(44,090,379) | $34,758,366 | ||||
| Share-based compensation expense | — | — | 1,076,865 | — | 1,076,865 | ||||
| Net loss | — | — | — | (23,964,211) | (23,964,211) | ||||
| Balance at December 31, 2023 | 15,966,053 | $15,966 | $79,909,644 | $(68,054,590) | $11,871,020 | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.